{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:44:49Z","timestamp":1792291489269,"version":"4.4.0"},"reference-count":102,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Cardiovascular\u2013Renal\u2013Hepatic\u2013Metabolic diseases are on the rise worldwide, creating major challenges for patient care and clinical research. Although these conditions share common mechanisms and often respond to similar treatments\u2014such as lifestyle changes and newer cardiometabolic drugs (e.g., SGLT2 inhibitors, GLP-1 receptor agonists)\u2014clinical management remains divided among multiple specialties. Recently proposed curricula in Cardiometabolic Medicine and Preventive Cardiology reflect an effort to address this fragmentation. In addition, recent studies reveal that hormonal deficiencies may increase cardiovascular risk and worsen heart failure, with emerging data showing that correcting these imbalances can improve exercise capacity and possibly reduce major cardiac events. To overcome gaps in care, we propose a new sub-specialty: Cardiovascular\u2013Endocrine\u2013Metabolic Medicine. This approach unifies three main pillars: (1) Lifestyle medicine, emphasizing nutrition, physical activity, and smoking cessation; (2) the Integrated Medical Management of obesity, diabetes, hypertension, dyslipidemia, heart failure with preserved ejection fraction, early-stage kidney disease, metabolic-associated liver disease, and related conditions; and (3) hormonal therapies, focused on optimizing sex hormones and other endocrine pathways to benefit cardiometabolic health. By bridging cardiology, endocrinology, and metabolic medicine, this sub-specialty offers a more seamless framework for patient care, speeds up the adoption of new treatments, and sets the stage for innovative research\u2014all critical steps in addressing the escalating cardiometabolic pandemic.<\/jats:p>","DOI":"10.3390\/biom15030373","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T03:18:22Z","timestamp":1741144702000},"page":"373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular\u2013Endocrine\u2013Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0420-7327","authenticated-orcid":false,"given":"Nikolaos","family":"Theodorakis","sequence":"first","affiliation":[{"name":"NT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, 47 Tirteou Str., 17564 Palaio Faliro, Greece"},{"name":"Department of Cardiology & Preventive Cardiology Outpatient Clinic, Amalia Fleming General Hospital, 14, 25th Martiou Str., 15127 Melissia, Greece"},{"name":"School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-5936","authenticated-orcid":false,"given":"Maria","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Department of Cardiology & Preventive Cardiology Outpatient Clinic, Amalia Fleming General Hospital, 14, 25th Martiou Str., 15127 Melissia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Krentz","sequence":"additional","affiliation":[{"name":"School of Life Course & Population Health Sciences, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., and Nikolaou, M. (2025). Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP\/GLP-1RAs. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010135"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","article-title":"Cardiometabolic HFpEF: NASH of the Heart","volume":"147","author":"Capone","year":"2023","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_17","first-page":"1","article-title":"Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: FINE-HEART Pooled Analysis of Cardiovascular, Kidney and Mortality Outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid Receptor Antagonists in Heart Failure: An Individual Patient-Level Meta-Analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide Versus Placebo in People with Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF DM Randomised Trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus Placebo in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jastreboff, A.M., le Roux, C.W., Stefanski, A., Aronne, L.J., Halpern, B., Wharton, S., Wilding, J.P.H., Perreault, L., Zhang, S., and Battula, R. (2024). Tirzepatide for Obesity Treatment and Diabetes Prevention. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2410819"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg Once Weekly in Patients with Non-Alcoholic Steatohepatitis-Related Cirrhosis: A Randomised, Placebo-Controlled Phase 2 Trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107516","DOI":"10.1016\/j.cct.2024.107516","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea: Rationale, Design, and Sample Baseline Characteristics of the SURMOUNT-OSA Phase 3 Trial","volume":"141","author":"Malhotra","year":"2024","journal-title":"Contemp. Clin. Trials"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone Treatment to Prevent or Revert Type 2 Diabetes in Men Enrolled in a Lifestyle Programme (T4DM): A Randomised, Double-Blind, Placebo-Controlled, 2-Year, Phase 3b Trial","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone Deficiency is Associated with Increased Risk of Mortality and Testosterone Replacement Improves Survival in Men with Type 2 Diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular Safety of Testosterone-Replacement Therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/eurjpc\/zwab020","article-title":"Multiple Hormonal and Metabolic Deficiency Syndrome Predicts Outcome in Heart Failure: The T.O.S.CA","volume":"28","author":"Cittadini","year":"2021","journal-title":"Registry. Eur. J. Prev. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/CRD.0000000000000350","article-title":"The Role of Testosterone in Patients with Heart Failure: A Systematic Review","volume":"29","author":"Park","year":"2021","journal-title":"Cardiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., Kreouzi, M., Hitas, C., Anagnostou, D., and Nikolaou, M. (2024). Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine. Diagnostics, 14.","DOI":"10.3390\/diagnostics14242831"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., Feretzakis, G., Kreouzi, M., Anagnostou, D., Hitas, C., Verykios, V.S., and Nikolaou, M. (2024). Growth Hormone Therapy in Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Endocrinol. Metab., dgae814.","DOI":"10.1210\/clinem\/dgae814"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.eprac.2022.07.004","article-title":"The Effectiveness of Thyroid Hormone Replacement Therapy on Heart Failure and Low-Triiodothyronine Syndrome: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"28","author":"Shi","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_47","first-page":"403","article-title":"Ghrelin: An Emerging Therapy for Heart Failure","volume":"102","author":"Theodorakis","year":"2025","journal-title":"Clin. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s42000-024-00587-2","article-title":"Testosterone Therapy for Functional Hypogonadism in Middle-Aged and Elderly Males: Current Evidence and Future Perspectives","volume":"23","author":"Theodorakis","year":"2024","journal-title":"Hormones"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jamainternmed.2023.7628","article-title":"Care Fragmentation, Care Continuity, and Care Coordination\u2014How They Differ and Why It Matters","volume":"184","author":"Kern","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1002\/nop2.1607","article-title":"Fragmented Care and Chronic Illness Patient Outcomes: A Systematic Review","volume":"10","author":"Joo","year":"2023","journal-title":"Nurs. Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/cdrp.cdrp_14_22","article-title":"Fragmentation of Care in Diabetes and Endocrinology\u2014What is the Way Forward?","volume":"1","author":"John","year":"2022","journal-title":"Chron. Diabetes Res. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.37765\/ajmc.2023.89374","article-title":"Diabetes, Gaps in Care Coordination, and Preventable Adverse Events","volume":"29","author":"Colvin","year":"2023","journal-title":"Am. J. Manag. Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.intcar.2021.100037","article-title":"Integrated Care and Diabetes: Challenges, Principles, and Opportunities","volume":"4","author":"Tan","year":"2021","journal-title":"Clin. Integr. Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.jacc.2019.08.1016","article-title":"Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives","volume":"74","author":"Shapiro","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/eurjpc\/zwab017","article-title":"EAPC Core Curriculum for Preventive Cardiology","volume":"29","author":"Wilhelm","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"dgaa261","DOI":"10.1210\/clinem\/dgaa261","article-title":"Cardiometabolic Medicine: Development of a New Subspecialty","volume":"105","author":"Saxon","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/XCE.0000000000000243","article-title":"Cardiometabolic Medicine: A Review of the Current Proposed Approaches to Revamped Training in the United States","volume":"10","author":"Soroosh","year":"2021","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/15598276221118494","article-title":"Lessons Learned from Blue Zones, Lifestyle Medicine Pillars, and Beyond: An Update on the Contributions of Behavior and Genetics to Wellbeing and Longevity","volume":"18","author":"Kreouzi","year":"2022","journal-title":"Am. J. Lifestyle Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Nikolaou, M., Theodorakis, N., Feretzakis, G., Vamvakou, G., Hitas, C., Kalantzi, S., Spyridaki, A., Apostolos, A., Verykios, V.S., and Toutouzas, K. (2024). Nationwide Mortality Trends from 2001 to 2020 in Greece: Health Policy Implications under the Scope of Aging Societies. Hellenic J. Cardiol.","DOI":"10.2139\/ssrn.4713286"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.amepre.2023.11.009","article-title":"Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010\u20132022","volume":"66","author":"Woodruff","year":"2024","journal-title":"Am. J. Prev. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e078523","DOI":"10.1136\/bmj-2023-078523","article-title":"Trends in Cardiovascular Disease Incidence Among 22 Million People in the UK Over 20 Years: Population-Based Study","volume":"385","author":"Conrad","year":"2024","journal-title":"BMJ"},{"key":"ref_62","unstructured":"World Health Organization (2024). Obesity and Overweight, WHO."},{"key":"ref_63","unstructured":"European Commission (2024). Overweight and Obesity\u2014BMI Statistics, Eurostat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of Type 2 Diabetes\u2014Global Burden of Disease and Forecasted Trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gavina, C., Carvalho, D.S., Valente, F., Bernardo, F., Dinis-Oliveira, R.J., Santos-Ara\u00fajo, C., and Taveira-Gomes, T. (2022). 20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9050149"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/17437199.2021.1967184","article-title":"What Sixty Years of Research Says About the Effectiveness of Patient Education on Health: A Second-Order Meta-Analysis","volume":"16","author":"Simonsmeier","year":"2022","journal-title":"Health Psychol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaa077","article-title":"2019 ESC\/EAS Guidelines for Management of Dyslipidaemia: Strengths and Limitations","volume":"7","author":"Zeitouni","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacc.2019.11.055","article-title":"Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review","volume":"75","author":"He","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/eurjpc\/zwaa141","article-title":"Personalized Exercise Prescription in the Prevention and Treatment of Arterial Hypertension: A Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension","volume":"29","author":"Hanssen","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0002-9149(89)90145-8","article-title":"Effect of Endurance Training on Blood Pressure at Rest, During Exercise, and During 24 Hours in Sedentary Men","volume":"63","author":"Hespel","year":"1989","journal-title":"Am. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2010.1710","article-title":"Effects of Aerobic and Resistance Training on Hemoglobin A1c Levels in Patients with Type 2 Diabetes: A Randomized Controlled Trial","volume":"304","author":"Church","year":"2010","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2012.3130","article-title":"Physical Activity and Mortality in Individuals with Diabetes Mellitus: A Prospective Study and Meta-Analysis","volume":"172","author":"Sluik","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"ref_76","first-page":"1440","article-title":"Study Examines Intermittent Fasting and Cardiovascular Mortality","volume":"331","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamacardio.2019.3796","article-title":"Implications of Specialist Density for Diabetes Care in the United States","volume":"4","author":"Patel","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/s41440-023-01461-1","article-title":"Endocrine Causes of Hypertension: Literature Review and Practical Approach","volume":"46","author":"Amar","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_79","first-page":"1","article-title":"Hypertension and the Kidneys","volume":"83","author":"Kalra","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"dgaa674","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in Participants with Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e023811","DOI":"10.1161\/JAHA.121.023811","article-title":"National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care, 47, S158\u2013S178.","DOI":"10.2337\/dc24-S009"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Cai, C.X., Hribar, M., Baxter, S., Goetz, K., Swaminathan, S.S., Flowers, A., Brown, E.N., Toy, B., Xu, B., and Chen, J. (2025). Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol., Online ahead of print.","DOI":"10.1001\/jamaophthalmol.2024.6555"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal Activation in Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000001380","article-title":"Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value","volume":"81","author":"Xie","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"418","DOI":"10.23736\/S2724-6051.21.04307-X","article-title":"Testosterone Replacement Therapy in Hypogonadal Male Patients with Hypogonadism and Heart Failure: A Meta-Analysis of Randomized Controlled Studies","volume":"74","author":"Cannarella","year":"2022","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632","article-title":"Testosterone Supplementation in Heart Failure: A Meta-Analysis","volume":"5","author":"Toma","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., Kreouzi, M., Hitas, C., Anagnostou, D., and Nikolaou, M. (2024). Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review. Diagnostics, 14.","DOI":"10.3390\/diagnostics14232677"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2666-7568(22)00115-5","article-title":"Testosterone: Therapeutic or Toxic for the Cardiovascular Health of Men?","volume":"3","author":"Michos","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.sxmr.2018.12.004","article-title":"Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome","volume":"7","author":"Hackett","year":"2019","journal-title":"Sex. Med. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jsxm.2022.05.145","article-title":"Cardiovascular Morbidity and Mortality in Men\u2014Findings from a Meta-Analysis on the Time-Related Measure of Risk of Exogenous Testosterone","volume":"19","author":"Fallara","year":"2022","journal-title":"J. Sex. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40264-015-0348-y","article-title":"Testosterone Replacement Therapy and Mortality in Older Men","volume":"39","author":"Hackett","year":"2016","journal-title":"Drug Saf."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41572-024-00547-5","article-title":"Premature Ovarian Insufficiency","volume":"10","author":"Touraine","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chon, S.J., Umair, Z., and Yoon, M.S. (2021). Premature Ovarian Insufficiency: Past, Present, and Future. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.672890"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"hoae065","DOI":"10.1093\/hropen\/hoae065","article-title":"Evidence-Based Guideline: Premature Ovarian Insufficiency","volume":"2024","author":"Panay","year":"2024","journal-title":"Hum. Reprod. Open"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of Premature Natural and Surgical Menopause with Incident Cardiovascular Disease","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Liu, J., Jin, X., Liu, W., Chen, W., Wang, L., Feng, Z., and Huang, J. (2023). The Risk of Long-Term Cardiometabolic Disease in Women with Premature or Early Menopause: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1131251"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(23)02800-3","article-title":"Optimising Health After Early Menopause","volume":"403","author":"Mishra","year":"2024","journal-title":"Lancet"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:15Z","timestamp":1760028435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":102,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["biom15030373"],"URL":"https:\/\/doi.org\/10.3390\/biom15030373","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}